Considering that TLR3 agonists are promising in clinical treatment as immunoadjuvants, our results may provide guidance for developing novel immunotherapy strategies for MIBC patients with FGFR3 mutations and promoting individualized tumor immunotherapy in the future. Here, FGFR3 is linked to neoplasm.